title: Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.
abstract: The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed.
authors.affiliation: VA Medical Center, White River Junction, Vermont, USA.|Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
authors.forename: Douglas J
authors.initials: DJ
authors.lastname: Robertson
authors.affiliation: University of California, San Francisco Medical Center, San Francisco, California, USA.
authors.forename: Jeffrey K
authors.initials: JK
authors.lastname: Lee
authors.affiliation: Baylor University Medical Center, Dallas, Texas, USA.
authors.forename: C Richard
authors.initials: CR
authors.lastname: Boland
authors.affiliation: VA Puget Sound Health Care System, University of Washington School of Medicine, Seattle, Washington, USA.
authors.forename: Jason A
authors.initials: JA
authors.lastname: Dominitz
authors.affiliation: Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
authors.forename: Francis M
authors.initials: FM
authors.lastname: Giardiello
authors.affiliation: Eastern VA Medical School, Norfolk, Virginia, USA.
authors.forename: David A
authors.initials: DA
authors.lastname: Johnson
authors.affiliation: San Francisco Veterans Affairs Medical Center, University of California, San Francisco, California, USA.
authors.forename: Tonya
authors.initials: T
authors.lastname: Kaltenbach
authors.affiliation: Oregon Health and Science University, Portland, Oregon.
authors.forename: David
authors.initials: D
authors.lastname: Lieberman
authors.affiliation: Kaiser Permanente Medical Center, Walnut Creek, California, USA.
authors.forename: Theodore R
authors.initials: TR
authors.lastname: Levin
authors.affiliation: Indiana University School of Medicine, Indianapolis, Indiana.
authors.forename: Douglas K
authors.initials: DK
authors.lastname: Rex
mesh_terms: D000236:Adenoma / Q000175:diagnosis*; D026683:Advisory Committees; D002277:Carcinoma / Q000175:diagnosis*; D003113:Colonoscopy; D015179:Colorectal Neoplasms / Q000175:diagnosis*; D004273:DNA, Neoplasm / Q000032:analysis; D055088:Early Detection of Cancer; D005243:Feces / Q000737:chemistry*; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D007120:Immunochemistry; D009780:Occult Blood; D012680:Sensitivity and Specificity; D012812:Sigmoidoscopy; D014481:United States
chemical_list: D004273:DNA, Neoplasm; D006454:Hemoglobins